JAMA reports semaglutide benefits hold across frailty levels

The wire

1. 01JAMA published an item reporting that semaglutide showed benefits across frailty levels in the patient groups examined.
2. 02Frailty is a common reason clinicians hesitate to start incretin therapy in older patients, so consistency of effect across frailty strata is directly relevant to prescribing decisions.
3. 03Full details on the cohort, endpoints and follow-up duration sit in the underlying analysis; subgroup findings of this kind are generally exploratory rather than definitive.

From the source

Semaglutide Demonstrates Benefits Across Frailty Levels

JAMA · 2026 Oct 2 · Anderer S et al.